Information Provided By:
Fly News Breaks for September 19, 2017
TEVA
Sep 19, 2017 | 06:59 EDT
Cantor Fitzgerald analyst Louise Chen says the valuation Teva Pharmaceutical received for its women's health franchise assets is higher than the Street expected. The sale should enable Teva to pay down sufficient debt to remain in compliance with its covenants at year end, Chen wrote yesterday in a research note. She believes the news should remove an overhang on the stock. The analyst keeps a Neutral rating on Teva with a $17 price target.
News For TEVA From the Last 2 Days
There are no results for your query TEVA
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.